These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Histology of the Fernandez reaction. An appraisal. Thomas J; Joseph M; Ramanujam K; Chacko CJ; Job CK Int J Lepr Other Mycobact Dis; 1981 Mar; 49(1):1-8. PubMed ID: 7195878 [TBL] [Abstract][Full Text] [Related]
5. Immunological studies in leprosy. III-Cutaneous response to antigens in spectrum of leprosy. Singh PK; Ratna ; Jain PK; Mital VP Indian J Lepr; 1984; 56(2):257-63. PubMed ID: 6548495 [TBL] [Abstract][Full Text] [Related]
7. Serial Mitsuda tests for identification of reactional tuberculoid and reactional borderline leprosy forms. Lastoria LC; Opromolla DV; Fleury RN; Habermann F; Curi PR Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):190-200. PubMed ID: 9728451 [TBL] [Abstract][Full Text] [Related]
8. [Tuberculoid leprosy and inflammatory borderline leprosy managed by desensitisation to lepromin. Preliminary results]. Saint-André P; Ferracci C; Baquillon G Acta Leprol; 1979; (76-77):303-9. PubMed ID: 121850 [No Abstract] [Full Text] [Related]
9. Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons form Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma. Chaudhuri S; Hajra SK; Mukherjee A; Saha B; Mazumder B; Chattapadhya D; Saha K Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):182-9. PubMed ID: 9728450 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta. Chaudhury S; Hajra SK; Mukerjee A; Saha B; Majumdar V; Chattapadhya D; Saha K Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):56-62. PubMed ID: 9207754 [TBL] [Abstract][Full Text] [Related]
11. [Therapy of tuberculoid and borderline leprosy by specific progressive desensitization to lepromin. Comparison between the classic method of progressive dilutions and the use of lepromin retard in aluminum hydroxide]. Saint-André P; Ferracci C; Baquillon G; Ridel PR Acta Leprol; 1981; 85():69-74. PubMed ID: 6805237 [No Abstract] [Full Text] [Related]
12. An eight-year field trial on antileprosy vaccines among high-risk household contacts in the Calcutta metropolis. Chaudhury S; Hazra SK; Saha B; Mazumder B; Biswas PC; Chattopadhya D; Saha K Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):389-94. PubMed ID: 7963911 [TBL] [Abstract][Full Text] [Related]
13. [On the significance for the classification and diagnosis of lepsory]. Schuppli R Schweiz Med Wochenschr; 1967 Mar; 97(10):307-8. PubMed ID: 5585383 [No Abstract] [Full Text] [Related]
14. Clinical and histopathological correlation in the classification of leprosy. Bhatia AS; Katoch K; Narayanan RB; Ramu G; Mukherjee A; Lavania RK Int J Lepr Other Mycobact Dis; 1993 Sep; 61(3):433-8. PubMed ID: 8228443 [TBL] [Abstract][Full Text] [Related]
15. Prognostic evaluation of cell mediated immunity in leprosy and correlation with clinicopathological status of leprosy patients. Aziz M; Malik A; Abbas SM; Vasenwala S; Kalam A Indian J Pathol Microbiol; 1996 Jan; 39(1):5-12. PubMed ID: 8755125 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of gene probes and its correlation with clinical profile of leprosy in children. Dayal R; Agarwal PK; Kalra K; Bharadwaj VP; Katoch VM; Katoch K Indian Pediatr; 1994 Dec; 31(12):1521-7. PubMed ID: 7875812 [TBL] [Abstract][Full Text] [Related]
17. [Leprosy in Brazil]. Araújo MG Rev Soc Bras Med Trop; 2003; 36(3):373-82. PubMed ID: 12908039 [TBL] [Abstract][Full Text] [Related]